Quantcast

Latest RNA Stories

2014-03-04 23:24:07

The revolutionary NickaseNinja™ combines a tandem pair of gRNAs in a single vector. Menlo Park, CA (PRWEB) March 04, 2014 DNA2.0 today announced the release of a set of CRISPR/Cas9 tools for genome editing and engineering. At the heart of DNA2.0’s CRISPR toolset is the revolutionary NickaseNinja system, which offers the high fidelity editing of Cas9 nickase plus guide RNA (gRNA) pairs, in a convenient single-vector format. By co-expressing two guide RNAs using dual RNA polymerase...

2014-03-04 16:03:43

Researchers at New York University and the University of Texas at Austin have discovered that carbohydrates serve as identifiers for cancer cells. Their findings, which appear in the journal Proceedings of the National Academy of Sciences, show how these molecules may serve as signals for cancer and explain what's going on inside these cells, pointing to new ways in which sugars function as a looking glass into the workings of their underlying structures. "Carbohydrates can tell us a lot...

2014-03-04 08:31:33

WESTBOROUGH, Mass., March 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 26(th) Annual ROTH Conference on Tuesday, March 11, 2014 at 4:30pm PST. Dr. Cauwenbergh will discuss the development of...

Fragile X Syndrome
2014-02-28 13:24:30

Brett Smith for redOrbit.com - Your Universe Online New research from a team of American researchers has found a genetic mechanism that shuts off the gene associated with fragile X syndrome – which causes developmental disorders such as mental retardation and autism. According to the team’s report in the journal Science, they were successfully able to a test drug that blocks this blocking mechanism. While it has been known that the syndrome is driven by the excessive repetition...

2014-02-27 16:28:10

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'- LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights. Corporate Strategy...

2014-02-24 12:27:26

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR(TM) delivery...

2014-02-24 08:28:42

DUBLIN, February 24, 2014 /PRNewswire/ -- (http://www.researchandmarkets.com/research/zppfx2/transcriptomics) have announced the addition of the "Concise Analysis on the International Transcriptomics Technologies Market - Forecast to 2019" [http://www.researchandmarkets.com/research/zppfx2/transcriptomics ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transcriptomics is one of the flourishing Omics technologies...

2014-02-24 08:27:38

WESTBOROUGH, Mass., Feb. 24, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 24(th) Annual Wall Street Analyst Forum on Monday, March 3, 2014 at 12:50pm EST. Dr. Cauwenbergh will discuss the...

2014-02-20 16:25:50

LA JOLLA, Calif., Feb. 20, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, February 27, 2014 at 5:00 pm...

2014-02-19 08:31:20

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy- LA JOLLA, Calif., Feb. 19, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical...


Latest RNA Reference Libraries

Brief Introduction To DNA Probes
2014-01-12 00:00:00

DNA probes help scientists to detect a specific gene in a long DNA sequence. According to Dr. Michael A. Pfaller, DNA probes are “single-stranded pieces of nucleic acid, labeled with a specific tracer (isotope, enzyme, or chromophore), that will hydrogen bond (hybridize) with complementary single-stranded pieces of DNA (or RNA) under the appropriate conditions of pH, temperature, and iconic strength.” The Foundation for Genomics and Population Health website has a helpful video about...

Caenorhabditis elegans
2014-01-12 00:00:00

Caenorhabditis elegans is a species of parasitic roundworm in the Nematoda phylum. It can be found in temperate regions, in many different areas of the world. It prefers to reside in nutrient rich soils. Its scientific name is derived from the Greek terms Caeno, meaning recent, rhabditis, meaning rod-like, and the Latin term elegans, which means elegant. It was first named by Maupas in 1900, but was not classified in the Caenorhabditis subgenus until 1952 by Osche. Caenorhabditis elegans...

Proceedings of the National Academy of Sciences
2012-05-29 11:19:42

The Proceedings of the National Academy of Sciences of the United States of America (PNAS) is a peer-reviewed scientific journal established in 1914 as the official journal of the US National Academy of Sciences. The first managing editor of the journal was mathematician Edwin Bidwell Wilson. As of May 2012, the editor-in-chief is Inder M. Verma. PNAS is published weekly in print, and daily online in PNAS Early Edition. The first issue of PNAS was published in 1915, and the journal...

Biophysical Journal
2012-05-28 10:08:02

The Biophysical Journal is a peer-reviewed scientific journal published biweekly by Cell Press on behalf of the Biophysical Society. It was established in 1960. The editor-in-chief is Edward Egelman. It covers all aspects of biophysics.  It is the leading international journal for original research in molecular, cellular, and system biophysics. Modern biophysics is a broad and rapidly advancing field encompassing the study of biological structures with a focus on mechanisms at the...

More Articles (5 articles) »
Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related